Valiglurax

Valiglurax
Identifiers
	IUPAC name N-(2H-pyrazolo[3,4-b]pyridin-3-yl)-1-(trifluoromethyl)isoquinolin-6-amine;
CAS Number	1976050-09-5;
PubChem CID	134191471;
IUPHAR/BPS	10135;
ChemSpider	88296853;
ChEMBL	ChEMBL4797139;
Chemical and physical data
Formula	C16H10F3N5
Molar mass	329.286 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC2=C(NN=C2N=C1)NC3=CC4=C(C=C3)C(=NC=C4)C(F)(F)F;
	InChI InChI=1S/C16H10F3N5/c17-16(18,19)13-11-4-3-10(8-9(11)5-7-20-13)22-15-12-2-1-6-21-14(12)23-24-15/h1-8H,(H2,21,22,23,24); Key:RUEXKBWCUUFJMY-UHFFFAOYSA-N;

Valiglurax (VU0652957) is an experimental drug that is a positive allosteric modulator for the glutamate receptor mGluR4. It was developed as a potential medication for the treatment of Parkinson's disease.^[1]^[2]

References

^ Panarese JD, Engers DW, Wu YJ, Bronson JJ, Macor JE, Chun A, et al. (March 2019). "Discovery of VU2957 (Valiglurax): An mGlu₄ Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease". ACS Medicinal Chemistry Letters. 10 (3): 255–260. doi:10.1021/acsmedchemlett.8b00426. PMC 6421540. PMID 30891122.
^ Panarese JD, Engers DW, Wu YJ, Guernon JM, Chun A, Gregro AR, et al. (January 2019). "The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu₄ PAM development candidate". Bioorganic & Medicinal Chemistry Letters. 29 (2): 342–346. doi:10.1016/j.bmcl.2018.10.050. PMID 30503632.